English

QLIFE HOLDING AB INTERIM REPORT Q3, 2021

Report this content

Covid-19 test sales moving to Egoo platform

FINANCIAL SUMMARY – THIRD QUARTER 2021

  • Revenue in the period amounted to kSEK 5,871 (5,062). Sales regards COVID-19 tests from the test service center as well as Egoo.Health devices and capsules for decentralized testing.
  • EBITDA for the period amounted to kSEK -12,229 (-5,043), and net loss kSEK -14,998 (-2,757).
  • The total cash flow in the third quarter amounted to kSEK -25,580 (-11,714).
  • Earnings per share before/after dilution for the third quarter amounted to SEK -1.13 (-0.25), calculated on weighted average number of shares in the period.

 FINANCIAL SUMMARY – JANUARY -SEPTEMBER 2021

  • Revenue in the period amounted to kSEK 27,529 (11,628). Revenue regards sales of COVID-19 tests from the test service center as well as Egoo.Health devices and capsules for decentralized testing.
  • EBITDA for the period amounted to kSEK -23,533 (-12,921), and net loss kSEK -33,533 (-12,598).
  • The total cash flow in the nine months period amounted to kSEK 61,907 (16,266).
  • The positive cash flow is related to the new issue of shares and exercise of warrants (TO1).
  • Shareholders equity as of 30 September amounted to kSEK 178,490 (99,299).
  • Earnings per share before/after dilution for the nine months amounted to SEK -2.70 (-1.22), calculated on weighted average number of shares in the period.

SIGNIFICANT EVENTS – THIRD QUARTER 2021

  • In July Qlife submitted a scientific study of the company’s COVID-19 test to Natures Scientific Reports for publication. The study demonstrates the potential of Qlife’s mobile test platform Egoo.Health and COVID-19 tests that can deliver exactly the same clinical quality as laboratory tests in 30 minutes.
     
  • Niklas Marschall left the Board of Qlife Holding AB and Qlife ApS.

SIGNIFICANT EVENTS AFTER END OF THIRD QUARTER 2021

  • In accordance with the decision at Qlife Holding’s Annual General assembly a Nomination committee has been convened. The Nomination committee consist of the following persons: Anita Otterheim Hjalmarsson, Sören Skjärbäk, Lars Bangsgaard and Mette Gross.

  • In November, the scientific study of the company's COVID-19 on the Egoo platform test was accepted for publication in Natures Scientific Reports. The complete study will be available shortly in Scientific Reports (https://www.nature.com/srep/).

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-11-2021 08:30 CET.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.

 

Subscribe

Documents & Links